Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$2.73
-8.4%
$3.84
$2.74
$7.63
$348.35M1.42720,597 shs1.22 million shs
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$5.49
-7.1%
$5.99
$3.91
$13.99
$377.77M1.58819,600 shs907,138 shs
Quanterix Co. stock logo
QTRX
Quanterix
$4.28
-7.8%
$5.99
$4.07
$19.18
$166.02M1.12562,606 shs1.41 million shs
Transcat, Inc. stock logo
TRNS
Transcat
$79.29
-2.6%
$77.18
$67.56
$147.12
$738.11M0.6977,445 shs72,501 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-1.32%-19.02%-19.68%-42.69%-51.78%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
+1.03%-5.29%+9.85%-6.93%-51.64%
Quanterix Co. stock logo
QTRX
Quanterix
-19.02%-13.27%-10.77%-40.59%-72.48%
Transcat, Inc. stock logo
TRNS
Transcat
-1.17%+2.88%-0.46%-0.21%-31.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
1.6783 of 5 stars
3.12.00.00.01.61.70.6
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
2.0949 of 5 stars
3.52.00.00.02.01.70.6
Quanterix Co. stock logo
QTRX
Quanterix
2.1498 of 5 stars
3.33.00.00.01.91.70.6
Transcat, Inc. stock logo
TRNS
Transcat
2.5541 of 5 stars
3.21.00.00.02.91.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.25
Hold$5.2592.31% Upside
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
3.00
Buy$25.29360.58% Upside
Quanterix Co. stock logo
QTRX
Quanterix
2.50
Moderate Buy$15.60264.49% Upside
Transcat, Inc. stock logo
TRNS
Transcat
2.40
Hold$111.5040.62% Upside

Current Analyst Ratings Breakdown

Latest QTRX, TRNS, CTKB, and EYPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Quanterix Co. stock logo
QTRX
Quanterix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/12/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$3.50 ➝ $3.00
5/9/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$4.00
5/8/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$33.00 ➝ $27.00
4/30/2025
Quanterix Co. stock logo
QTRX
Quanterix
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Quanterix Co. stock logo
QTRX
Quanterix
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$12.00 ➝ $8.00
3/25/2025
Quanterix Co. stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
3/25/2025
Quanterix Co. stock logo
QTRX
Quanterix
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$28.00 ➝ $18.00
3/19/2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$6.00 ➝ $6.00
3/18/2025
Quanterix Co. stock logo
QTRX
Quanterix
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
3/6/2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$33.00 ➝ $33.00
(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$197.05M1.77$0.01 per share206.16$2.90 per share0.94
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
$43.27M8.73N/AN/A$5.66 per share0.97
Quanterix Co. stock logo
QTRX
Quanterix
$135.44M1.23N/AN/A$9.25 per share0.46
Transcat, Inc. stock logo
TRNS
Transcat
$272.20M2.71$2.92 per share27.14$30.19 per share2.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/AN/A-5.05%-2.58%-2.05%N/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%N/A
Quanterix Co. stock logo
QTRX
Quanterix
-$28.35M-$1.03N/AN/AN/A-30.12%-11.74%-9.66%N/A
Transcat, Inc. stock logo
TRNS
Transcat
$13.65M$1.8542.8630.15N/A6.22%7.23%5.67%5/19/2025 (Estimated)

Latest QTRX, TRNS, CTKB, and EYPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q4 2025
Transcat, Inc. stock logo
TRNS
Transcat
$0.66N/AN/AN/A$76.40 millionN/A
5/12/2025Q1 2025
Quanterix Co. stock logo
QTRX
Quanterix
-$0.69-$0.53+$0.16-$0.53$28.27 million$30.33 million
5/8/2025Q1 2025
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$0.04-$0.09-$0.05-$0.09$43.18 million$41.46 million
5/7/2025Q1 2025
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million
3/17/2025Q4 2024
Quanterix Co. stock logo
QTRX
Quanterix
-$0.27-$0.30-$0.03-$0.30$34.93 million$35.16 million
3/5/2025Q4 2024
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/AN/AN/AN/AN/A
Quanterix Co. stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A
Transcat, Inc. stock logo
TRNS
Transcat
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.21
5.47
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
N/A
5.50
5.45
Quanterix Co. stock logo
QTRX
Quanterix
N/A
10.07
9.16
Transcat, Inc. stock logo
TRNS
Transcat
0.14
2.42
1.98

Institutional Ownership

CompanyInstitutional Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
69.46%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
99.41%
Quanterix Co. stock logo
QTRX
Quanterix
86.48%
Transcat, Inc. stock logo
TRNS
Transcat
98.34%

Insider Ownership

CompanyInsider Ownership
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
9.60%
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
4.74%
Quanterix Co. stock logo
QTRX
Quanterix
6.90%
Transcat, Inc. stock logo
TRNS
Transcat
2.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
500127.60 million116.45 millionOptionable
EyePoint Pharmaceuticals, Inc. stock logo
EYPT
EyePoint Pharmaceuticals
12068.81 million65.02 millionOptionable
Quanterix Co. stock logo
QTRX
Quanterix
46038.79 million35.87 millionOptionable
Transcat, Inc. stock logo
TRNS
Transcat
9209.31 million9.10 millionOptionable

Recent News About These Companies

Transcat, Inc. stock logo
Transcat (TRNS) to Release Earnings on Monday
Transcat (TRNS) to Release Quarterly Earnings on Monday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytek Biosciences stock logo

Cytek Biosciences NASDAQ:CTKB

$2.73 -0.25 (-8.39%)
As of 04:00 PM Eastern

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

EyePoint Pharmaceuticals stock logo

EyePoint Pharmaceuticals NASDAQ:EYPT

$5.49 -0.42 (-7.11%)
As of 04:00 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Quanterix stock logo

Quanterix NASDAQ:QTRX

$4.28 -0.36 (-7.76%)
As of 04:00 PM Eastern

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Transcat stock logo

Transcat NASDAQ:TRNS

$79.29 -2.14 (-2.63%)
As of 04:00 PM Eastern

Transcat, Inc. provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services. This segment also provides CalTrak, a proprietary document and asset management system that is used to manage the workflow of its calibration service centers and customers' assets; and Compliance, Control and Cost, an online customer portal that provides its customers with web-based asset management capability, as well as a safe and secure off-site archive of calibration and other service records. The Distribution segment sells and rents test, measurement, and control instruments for customers' test and measurement instrumentation needs, as well as value added services, such as calibration/certification of equipment purchase, equipment rental, used equipment for sale, and equipment kitting. This segment markets and sells its products through website, digital and print advertising, proactive outbound sales, and an inbound call center. The company provides services and products to highly regulated industries, principally life science, which includes companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated industries; and additional industries, including aerospace and defense industrial manufacturing, energy and utilities, and other industries that require accuracy in processes and confirmation of the capabilities of their equipment. Transcat, Inc. was incorporated in 1964 and is headquartered in Rochester, New York.